Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

MLA

Apter, Dan, et al. “Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial.” Clinical and Vaccine Immunology (Formerly CDLI), vol. 22, no. 4, Feb. 2015, pp. 361–73. EBSCOhost, https://doi.org/10.1128/CVI.00591-14.

APA

Apter, D., Wheeler, C. M., Paavonen, J., Castellsagué, X., Garland, S. M., Skinner, S. R., Naud, P., Salmerón, J., Chow, S.-N., Kitchener, H. C., Teixeira, J. C., Jaisamrarn, U., Limson, G., Szarewski, A., Romanowski, B., Aoki, F. Y., Schwarz, T. F., Poppe, W. A. J., Bosch, F. X., … Dubin, G. (2015). Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial. Clinical and Vaccine Immunology (Formerly CDLI), 22(4), 361–373. https://doi.org/10.1128/CVI.00591-14

Chicago

Apter, Dan, Cosette M. Wheeler, Jorma Paavonen, Xavier Castellsagué, Suzanne M. Garland, S. Rachel Skinner, Paulo Naud, et al. 2015. “Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial.” Clinical and Vaccine Immunology (Formerly CDLI) 22 (4): 361–73. doi:10.1128/CVI.00591-14.